Effect Of Age And Lenvatinib Treatment On Overall Survival For Patients With I-131-Refractory Differentiated Thyroid Cancer In Select

6048 Background: Lenvatinib (LEN) significantly prolonged progression-free survival (PFS) vs placebo (PB) in the phase 3 SELECT trial of patients (pts) with 131I-refractory differentiated thyroid cancer (RR-DTC)–a benefit maintained in both younger ( ≤ 65, median 56 years [y]) and older ( u003e 65, median 71 y) pts. In SELECT, median overall survival (OS) was not reached at data cutoff, and OS was not significantly different between LEN and PB (HR 0.73; 95% CI 0.50-1.07; P = 0.103). Here we examine the effect of age on OS in SELECT. Methods: Pts with RR-DTC and independent radiologic documentation of disease progression were stratified by region, prior VEGF-targeted therapy, and age (younger: LEN, n = 155; PB, n = 81 vs older: LEN, n = 106; PB, n = 50) and randomized 2:1 to LEN or PB. Median follow-up was 17.1 months at primary data cutoff (Nov 15, 2013); 83% of pts on PB crossed over to LEN following confirmed disease progression. Results: Median OS was not reached in any group except in older PB-treated pts...